Global End-Stage Renal Disease (ESRD) Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global End-Stage Renal Disease (ESRD) Drugs Market Size and Outlook 2025-31

The global End-Stage Renal Disease (ESRD) Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the End-Stage Renal Disease (ESRD) Drugs Industry Forecast looks at past sales and reviews total world End-Stage Renal Disease (ESRD) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected End-Stage Renal Disease (ESRD) Drugs sales for 2025 through 2031. With End-Stage Renal Disease (ESRD) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world End-Stage Renal Disease (ESRD) Drugs industry. This Insight Report provides a comprehensive analysis of the global End-Stage Renal Disease (ESRD) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on End-Stage Renal Disease (ESRD) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global End-Stage Renal Disease (ESRD) Drugs market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for End-Stage Renal Disease (ESRD) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global End-Stage Renal Disease (ESRD) Drugs. This report presents a comprehensive overview, market shares, and growth opportunities of End-Stage Renal Disease (ESRD) Drugs market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Calcium Succinate &nbsp;&nbsp;&nbsp; Mk-3866 &nbsp;&nbsp;&nbsp; Pacritinib &nbsp;&nbsp;&nbsp; Sanguinate &nbsp;&nbsp;&nbsp; Tesidolumab &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; ICU &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; CTI BioPharma Corp &nbsp;&nbsp;&nbsp; Merck & Co Inc &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Prolong Pharmaceuticals LLC &nbsp;&nbsp;&nbsp; VESSL Therapeutics Ltd Key Questions Addressed in this Report What is the 10-year outlook for the global End-Stage Renal Disease (ESRD) Drugs market? What factors are driving End-Stage Renal Disease (ESRD) Drugs market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do End-Stage Renal Disease (ESRD) Drugs market opportunities vary by end market size? How does End-Stage Renal Disease (ESRD) Drugs break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global End-Stage Renal Disease (ESRD) Drugs Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for End-Stage Renal Disease (ESRD) Drugs by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for End-Stage Renal Disease (ESRD) Drugs by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 End-Stage Renal Disease (ESRD) Drugs Segment by Type &nbsp;2.2.1 Calcium Succinate &nbsp;2.2.2 Mk-3866 &nbsp;2.2.3 Pacritinib &nbsp;2.2.4 Sanguinate &nbsp;2.2.5 Tesidolumab &nbsp;2.2.6 Others &nbsp;2.3 End-Stage Renal Disease (ESRD) Drugs Sales by Type &nbsp;2.3.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global End-Stage Renal Disease (ESRD) Drugs Sale Price by Type (2020-2025) &nbsp;2.4 End-Stage Renal Disease (ESRD) Drugs Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 ICU &nbsp;2.4.4 Others &nbsp;2.5 End-Stage Renal Disease (ESRD) Drugs Sales by Application &nbsp;2.5.1 Global End-Stage Renal Disease (ESRD) Drugs Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global End-Stage Renal Disease (ESRD) Drugs Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global End-Stage Renal Disease (ESRD) Drugs Breakdown Data by Company &nbsp;3.1.1 Global End-Stage Renal Disease (ESRD) Drugs Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Company (2020-2025) &nbsp;3.2 Global End-Stage Renal Disease (ESRD) Drugs Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Company (2020-2025) &nbsp;3.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global End-Stage Renal Disease (ESRD) Drugs Sale Price by Company &nbsp;3.4 Key Manufacturers End-Stage Renal Disease (ESRD) Drugs Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers End-Stage Renal Disease (ESRD) Drugs Product Location Distribution &nbsp;3.4.2 Players End-Stage Renal Disease (ESRD) Drugs Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for End-Stage Renal Disease (ESRD) Drugs by Geographic Region &nbsp;4.1 World Historic End-Stage Renal Disease (ESRD) Drugs Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global End-Stage Renal Disease (ESRD) Drugs Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global End-Stage Renal Disease (ESRD) Drugs Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic End-Stage Renal Disease (ESRD) Drugs Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas End-Stage Renal Disease (ESRD) Drugs Sales Growth &nbsp;4.4 APAC End-Stage Renal Disease (ESRD) Drugs Sales Growth &nbsp;4.5 Europe End-Stage Renal Disease (ESRD) Drugs Sales Growth &nbsp;4.6 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Growth 5 Americas &nbsp;5.1 Americas End-Stage Renal Disease (ESRD) Drugs Sales by Country &nbsp;5.1.1 Americas End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) &nbsp;5.1.2 Americas End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) &nbsp;5.2 Americas End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2025) &nbsp;5.3 Americas End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC End-Stage Renal Disease (ESRD) Drugs Sales by Region &nbsp;6.1.1 APAC End-Stage Renal Disease (ESRD) Drugs Sales by Region (2020-2025) &nbsp;6.1.2 APAC End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2020-2025) &nbsp;6.2 APAC End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2025) &nbsp;6.3 APAC End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe End-Stage Renal Disease (ESRD) Drugs by Country &nbsp;7.1.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) &nbsp;7.1.2 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) &nbsp;7.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2025) &nbsp;7.3 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs by Country &nbsp;8.1.1 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of End-Stage Renal Disease (ESRD) Drugs &nbsp;10.3 Manufacturing Process Analysis of End-Stage Renal Disease (ESRD) Drugs &nbsp;10.4 Industry Chain Structure of End-Stage Renal Disease (ESRD) Drugs 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 End-Stage Renal Disease (ESRD) Drugs Distributors &nbsp;11.3 End-Stage Renal Disease (ESRD) Drugs Customer 12 World Forecast Review for End-Stage Renal Disease (ESRD) Drugs by Geographic Region &nbsp;12.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size Forecast by Region &nbsp;12.1.1 Global End-Stage Renal Disease (ESRD) Drugs Forecast by Region (2026-2031) &nbsp;12.1.2 Global End-Stage Renal Disease (ESRD) Drugs Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global End-Stage Renal Disease (ESRD) Drugs Forecast by Type (2026-2031) &nbsp;12.7 Global End-Stage Renal Disease (ESRD) Drugs Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 CTI BioPharma Corp &nbsp;13.1.1 CTI BioPharma Corp Company Information &nbsp;13.1.2 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolios and Specifications &nbsp;13.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 CTI BioPharma Corp Main Business Overview &nbsp;13.1.5 CTI BioPharma Corp Latest Developments &nbsp;13.2 Merck & Co Inc &nbsp;13.2.1 Merck & Co Inc Company Information &nbsp;13.2.2 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolios and Specifications &nbsp;13.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Merck & Co Inc Main Business Overview &nbsp;13.2.5 Merck & Co Inc Latest Developments &nbsp;13.3 Novartis AG &nbsp;13.3.1 Novartis AG Company Information &nbsp;13.3.2 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolios and Specifications &nbsp;13.3.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Novartis AG Main Business Overview &nbsp;13.3.5 Novartis AG Latest Developments &nbsp;13.4 Prolong Pharmaceuticals LLC &nbsp;13.4.1 Prolong Pharmaceuticals LLC Company Information &nbsp;13.4.2 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolios and Specifications &nbsp;13.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Prolong Pharmaceuticals LLC Main Business Overview &nbsp;13.4.5 Prolong Pharmaceuticals LLC Latest Developments &nbsp;13.5 VESSL Therapeutics Ltd &nbsp;13.5.1 VESSL Therapeutics Ltd Company Information &nbsp;13.5.2 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolios and Specifications &nbsp;13.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 VESSL Therapeutics Ltd Main Business Overview &nbsp;13.5.5 VESSL Therapeutics Ltd Latest Developments 14 Research Findings and Conclusion

Report	Global End-Stage Renal Disease (ESRD) Drugs Market Growth 2025-2031
Selected License	Single ID:LPI23842

Buyer Information

Order Summary